{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:05:07Z","timestamp":1779966307796,"version":"3.53.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006302","name":"Universidad de Alcal\u00e1","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Differentiating inflammatory bowel disease (IBD) flares from infectious complications in patients on anti-TNF\u03b1 therapy presents a significant diagnostic challenge. This case report describes a 54-year-old woman with ileocolic Crohn\u2019s disease on adalimumab who presented with systemic and gastrointestinal symptoms mimicking a flare. Initial computed tomography revealed enteritis, mesenteric lymphadenopathy, and extensive inferior vena cava thrombosis. Despite treatment with corticosteroids and broad-spectrum antibiotics, the patient developed respiratory symptoms. Further evaluation confirmed disseminated tuberculosis (TB) through PCR and culture from a bronchoalveolar lavage and histopathological analysis of a lymph node. Adalimumab was discontinued, and the patient was successfully treated with anti-tuberculous therapy and anticoagulation, leading to progressive clinical improvement. This case underscores the importance of a broad differential diagnosis in immunosuppressed IBD patients, as opportunistic infections like TB can mimic IBD flares and require invasive diagnostics for definitive confirmation, especially when systemic symptoms and thrombosis are present.<\/jats:p>","DOI":"10.1007\/s12328-026-02303-6","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:23:42Z","timestamp":1772879022000},"page":"516-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Flare: A Case of Disseminated Tuberculosis and Thrombosis Masquerading as IBD Exacerbation"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-2739","authenticated-orcid":false,"given":"Germ\u00e1n","family":"Ram\u00edrez-Olivencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Caravaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Sanz","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"de la Serna Gamboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio D\u00edaz","family":"Villalonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"2303_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196419","author":"CAM Cavalli","year":"2023","unstructured":"Cavalli CAM, Gabbiadini R, Dal Buono A, et al. Lung involvement in inflammatory bowel diseases: shared pathways and unwanted connections. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12196419.","journal-title":"J Clin Med"},{"key":"2303_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.amjmed.2019.07.007","volume":"133","author":"A Massart","year":"2020","unstructured":"Massart A, Hunt DP. Pulmonary manifestations of inflammatory bowel disease. Am J Med. 2020;133:39\u201343. https:\/\/doi.org\/10.1016\/j.amjmed.2019.07.007.","journal-title":"Am J Med"},{"key":"2303_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3748\/wjg.v20.i1.133","volume":"20","author":"DG Lu","year":"2014","unstructured":"Lu DG, Ji XQ, Liu X, et al. Pulmonary manifestations of Crohn\u2019s disease. World J Gastroenterol. 2014;20:133\u201341. https:\/\/doi.org\/10.3748\/wjg.v20.i1.133.","journal-title":"World J Gastroenterol"},{"key":"2303_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188912","author":"I Preotesoiu","year":"2025","unstructured":"Preotesoiu I, Alexandrescu L, Cimpineanu B, et al. From gut to lungs: the hidden respiratory impacts of IBD: a systematic review of the literature. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26188912.","journal-title":"Int J Mol Sci"},{"key":"2303_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18:1\u201337. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad108.","journal-title":"J Crohns Colitis"},{"key":"2303_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/ajg.2013.138","volume":"108","author":"AC Ford","year":"2013","unstructured":"Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268\u201376. https:\/\/doi.org\/10.1038\/ajg.2013.138.","journal-title":"Am J Gastroenterol"},{"key":"2303_CR7","doi-asserted-by":"publisher","first-page":"12567","DOI":"10.1136\/bmjopen-2016","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:12567. https:\/\/doi.org\/10.1136\/bmjopen-2016.","journal-title":"BMJ Open"},{"key":"2303_CR8","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3748\/wjg.v24.i25.2764","volume":"24","author":"BL Cao","year":"2018","unstructured":"Cao BL, Qasem A, Sharp RC, et al. Systematic review and meta-analysis on the association of tuberculosis in Crohn\u2019s disease patients treated with tumor necrosis factor-\u03b1 inhibitors (Anti-TNF\u03b1). World J Gastroenterol. 2018;24:2764\u201375. https:\/\/doi.org\/10.3748\/wjg.v24.i25.2764.","journal-title":"World J Gastroenterol"},{"key":"2303_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gastrohep.2020.04.006","volume":"44","author":"S Riestra","year":"2021","unstructured":"Riestra S, Taxonera C, Zabana Y, et al. Recommendations of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2021;44:51\u201366. https:\/\/doi.org\/10.1016\/j.gastrohep.2020.04.006.","journal-title":"Gastroenterol Hepatol"},{"key":"2303_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ecco-jcc\/jjab141","volume":"16","author":"R Feakins","year":"2022","unstructured":"Feakins R, Torres J, Borralho-Nunes P, et al. ECCO topical review on clinicopathological spectrum and differential diagnosis of inflammatory bowel disease. J Crohns Colitis. 2022;16:343\u201368. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab141.","journal-title":"J Crohns Colitis"},{"key":"2303_CR11","doi-asserted-by":"crossref","unstructured":"Gecse KB, Vermeire S. Review Differential diagnosis of inflammatory bowel disease: imitations and complications. vol. 3. 2018.","DOI":"10.1016\/S2468-1253(18)30159-6"},{"key":"2303_CR12","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/j.1440-1746.2010.06407.x","volume":"25","author":"IC Lawrance","year":"2010","unstructured":"Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol (Australia). 2010;25:1732\u20138. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06407.x.","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"2303_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","volume":"115","author":"S Kedia","year":"2020","unstructured":"Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on Infliximab or Adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115:340\u20139. https:\/\/doi.org\/10.14309\/ajg.0000000000000527.","journal-title":"Am J Gastroenterol"},{"key":"2303_CR14","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ G\u00f3mez-Reino","year":"2003","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Rodr\u00edguez Valverde V, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122\u20137. https:\/\/doi.org\/10.1002\/art.11137.","journal-title":"Arthritis Rheum"},{"key":"2303_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.20411\/pai.v5i1.349","volume":"5","author":"K Thomas","year":"2020","unstructured":"Thomas K, Hadziyannis E, Hatzara C, et al. Conversion and reversion rates of tuberculosis screening assays in patients with rheumatic diseases and negative baseline screening under long-term biologic treatment. Pathog Immun. 2020;5:34\u201351. https:\/\/doi.org\/10.20411\/pai.v5i1.349.","journal-title":"Pathog Immun"},{"key":"2303_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/acr2.11070","volume":"1","author":"D Pattanaik","year":"2019","unstructured":"Pattanaik D, Gupta S, Islam S, et al. Conversion of tuberculosis screening tests during biologic therapy among veteran patient population with rheumatic disease. ACR Open Rheumatol. 2019;1:542\u20135. https:\/\/doi.org\/10.1002\/acr2.11070.","journal-title":"ACR Open Rheumatol"},{"key":"2303_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ibd.20496","volume":"14","author":"Y Zabana","year":"2008","unstructured":"Zabana Y, Dom\u00e8nech E, L\u00f3pez San Rom\u00e1n A, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008;14:1387\u201391. https:\/\/doi.org\/10.1002\/ibd.20496.","journal-title":"Inflamm Bowel Dis"},{"key":"2303_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.021","author":"M Ma\u00f1osa","year":"2013","unstructured":"Ma\u00f1osa M, Dom\u00e8nech E, Cabr\u00e9 E. Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: still room for improvement. J Crohns Colitis. 2013. https:\/\/doi.org\/10.1016\/j.crohns.2013.04.021.","journal-title":"J Crohns Colitis"},{"key":"2303_CR19","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.16.1.17","volume":"16","author":"DI Park","year":"2018","unstructured":"Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res. 2018;16:17. https:\/\/doi.org\/10.5217\/ir.2018.16.1.17.","journal-title":"Intest Res"},{"key":"2303_CR20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjy104","volume":"12","author":"C Taxonera","year":"2018","unstructured":"Taxonera C, Ponferrada \u00c1, Riestra S, et al. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12:1270\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy104.","journal-title":"J Crohns Colitis"},{"key":"2303_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.5217\/ir.2016.14.2.146","volume":"14","author":"JW Lee","year":"2016","unstructured":"Lee JW, Choi CH, Park JH, et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intest Res. 2016;14:146\u201351. https:\/\/doi.org\/10.5217\/ir.2016.14.2.146.","journal-title":"Intest Res"},{"key":"2303_CR22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/MEG.0b013e32834b9544","volume":"23","author":"Z Lin","year":"2011","unstructured":"Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2011;23:1100\u201310. https:\/\/doi.org\/10.1097\/MEG.0b013e32834b9544.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2303_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.crohns.2013.11.008","volume":"8","author":"C Debeuckelaere","year":"2014","unstructured":"Debeuckelaere C, De M, Van PB, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis. 2014;8:550\u20137. https:\/\/doi.org\/10.1016\/j.crohns.2013.11.008.","journal-title":"J Crohns Colitis"},{"key":"2303_CR24","first-page":"241","volume":"28","author":"C \u00c7eki\u00e7","year":"2015","unstructured":"\u00c7eki\u00e7 C, Aslan F, Vatansever S, et al. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. Ann Gastroenterol. 2015;28:241\u20136.","journal-title":"Ann Gastroenterol"},{"key":"2303_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241265013","author":"MJ Kim","year":"2024","unstructured":"Kim MJ, Kim YJ, Jeong D, et al. Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-\u03b1 agents: a nationwide population-based cohort study. Therap Adv Gastroenterol. 2024. https:\/\/doi.org\/10.1177\/17562848241265013.","journal-title":"Therap Adv Gastroenterol"},{"key":"2303_CR26","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3748\/wjg.v21.i11.3308","volume":"21","author":"ES Kim","year":"2015","unstructured":"Kim ES, Song GA, Cho KB, et al. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol. 2015;21:3308\u201316. https:\/\/doi.org\/10.3748\/wjg.v21.i11.3308.","journal-title":"World J Gastroenterol"},{"key":"2303_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12664-022-01252-5","volume":"41","author":"P Kumar","year":"2022","unstructured":"Kumar P, Vuyyuru SK, Kante B, et al. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: a real-world cohort analysis. Indian J Gastroenterol. 2022;41:446\u201355. https:\/\/doi.org\/10.1007\/s12664-022-01252-5.","journal-title":"Indian J Gastroenterol"},{"key":"2303_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","volume":"7","author":"A Jauregui-Amezaga","year":"2013","unstructured":"Jauregui-Amezaga A, Turon F, Ord\u00e1s I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis. 2013;7:208\u201312. https:\/\/doi.org\/10.1016\/j.crohns.2012.05.012.","journal-title":"J Crohns Colitis"},{"key":"2303_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/apt.13851","volume":"45","author":"SN Hong","year":"2017","unstructured":"Hong SN, Kim HJ, Kim KH, et al. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2017;45:253\u201363. https:\/\/doi.org\/10.1111\/apt.13851.","journal-title":"Aliment Pharmacol Ther"},{"key":"2303_CR30","unstructured":"Oseph Eane JK, Haron Ershon SG, Harm PD, et al. The New Eng land Jour nal of Medicine tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent abstract. vol. 345. 2001."},{"key":"2303_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.03.004","author":"C Abreu","year":"2013","unstructured":"Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-\u03b1 treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis. 2013. https:\/\/doi.org\/10.1016\/j.crohns.2013.03.004.","journal-title":"J Crohns Colitis"},{"key":"2303_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231179871","author":"M de Freitas Cardoso Azevedo","year":"2023","unstructured":"de Freitas Cardoso Azevedo M, Barros LL, Fernandes Justus F, et al. Active tuberculosis in inflammatory bowel disease patients: a case\u2013control study. Therap Adv Gastroenterol. 2023. https:\/\/doi.org\/10.1177\/17562848231179871.","journal-title":"Therap Adv Gastroenterol"},{"key":"2303_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4166\/kjg.2020.75.1.29","volume":"75","author":"J Kim","year":"2020","unstructured":"Kim J, Im JP, Yim JJ, et al. Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-tumor necrosis factor therapy. Korean J Gastroenterol. 2020;75:29\u201338. https:\/\/doi.org\/10.4166\/kjg.2020.75.1.29.","journal-title":"Korean J Gastroenterol"},{"key":"2303_CR34","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/meg.0000000000001469","volume":"31","author":"M Sousa","year":"2019","unstructured":"Sousa M, Ladeira I, Ponte A, et al. Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center. Eur J Gastroenterol Hepatol. 2019;31:1099\u2013102. https:\/\/doi.org\/10.1097\/meg.0000000000001469.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2303_CR35","first-page":"2399","volume":"2022","author":"A Georgieva","year":"2022","unstructured":"Georgieva A, Atanassova A, Mirchev M. Rates of latent and active tuberculosis in BGC vaccinated, immunosuppressed Crohn\u2019s disease patients form Bulgaria before and during anti-tumor necrosis factor therapy. Eur Rev Med Pharmacol Sci. 2022;2022:2399\u2013407.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2303_CR36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of Infliximab therapy. Arthritis Rheum. 2004;50:372\u20139. https:\/\/doi.org\/10.1002\/art.20009.","journal-title":"Arthritis Rheum"},{"key":"2303_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cid\/cit780","volume":"58","author":"C Dentan","year":"2014","unstructured":"Dentan C, Epaulard O, Seynaeve D, et al. Active tuberculosis and venous thromboembolism: association according to international classification of diseases, ninth revision hospital discharge diagnosis codes. Clin Infect Dis. 2014;58:495\u2013501. https:\/\/doi.org\/10.1093\/cid\/cit780.","journal-title":"Clin Infect Dis"},{"key":"2303_CR38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11239-020-02211-7","volume":"51","author":"C Danwang","year":"2021","unstructured":"Danwang C, Bigna JJ, Awana AP, et al. Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis. J Thromb Thrombolysis. 2021;51:502\u201312. https:\/\/doi.org\/10.1007\/s11239-020-02211-7.","journal-title":"J Thromb Thrombolysis"},{"key":"2303_CR39","doi-asserted-by":"publisher","first-page":"S775","DOI":"10.14309\/01.ajg.0000953728.18083.ce","volume":"10S","author":"M Facey","year":"2023","unstructured":"Facey M, Khurana A, Adil S, et al. Long term risk of venous thromboembolism in patients with crohn\u2019s disease treated with biologics or immunomodulators. Am J Gastroenterol. 2023;10S:S775\u20136.","journal-title":"Am J Gastroenterol"},{"key":"2303_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/ecco-jcc\/jjx162","volume":"12","author":"P Sarlos","year":"2018","unstructured":"Sarlos P, Szemes K, Hegyi P, et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis. J Crohns Colitis. 2018;12:489\u201398. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx162.","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02303-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02303-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02303-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:22:40Z","timestamp":1779963760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02303-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02303-6","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no financial or non-financial competing interests related to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report, including clinical details and accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}